Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine

Clinical Genitourinary Cancer

Volumn 10, Issue 1, 2012, Pages 43-46

  Kim, Joseph W ^a   Madan, Ravi A ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunologic response; Prostate Cancer; PROSTVAC; PSA TRICOM

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIPYRETIC AGENT; BICALUTAMIDE; CANCER VACCINE; CARISOPRODOL; ETODOLAC; FENTANYL; HYDROCODONE BITARTRATE PLUS PARACETAMOL; LIDOCAINE; METHADONE; PROSTATE SPECIFIC ANTIGEN; PSA TRICOM; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CASE REPORT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GLEASON SCORE; HUMAN; IMMUNE RESPONSE; INJECTION SITE CELLULITIS; INJECTION SITE REACTION; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

CANCER VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84863177228     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.09.003     Document Type: Article

References (15)

1. A. Jemal, R. Siegel, J. Xu Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. M. Norgaard, A.O. Jensen, J.B. Jacobsen Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007) J Urol 184 2010 162 167
3. W. Zhu, D.S. Zhu, R.A. Madan Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway Am J Ther 17 2010 176 181
4. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
5. R.A. Madan, P.M. Arlen, M. Mohebtash Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer Expert Opin Investig Drugs 18 2009 1001 1011
6. P.W. Kantoff, T.J. Schuetz, B.A. Blumenstein Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
7. J.L. Gulley, P.M. Arlen, R.A. Madan Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunol Immunother 59 2010 663 674
8. S. Halabi, N.J. Vogelzang, A.B. Kornblith Pain predicts overall survival in men with metastatic castration-refractory prostate cancer J Clin Oncol 26 2008 2544 2549
9. S. Halabi, E.J. Small, P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237 (Pubitemid 46606398)
10. A Trial of PROSTVAC +/ GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Prospect) www.ClinicalTrials.gov [Web site]. Accessed: June 2011 http://www. clinicaltrials.gov/ct2/show/NCT01322490 Accessed: September 21, 2011
11. H.I. Scher, S. Halabi, I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
12. J.L. Gulley, C.G. Drake Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research Clin Cancer Res 17 2011 3884 3891
13. R.A. Madan, J.L. Gulley The current and emerging role of immunotherapy in prostate cancer Clin Genitourin Cancer 8 2010 10 16
14. P.W. Kantoff, C.S. Higano, N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
15. W.D. Stein, J.L. Gulley, J. Schlom Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy Clin Cancer Res 17 2011 907 917